A BST RACT : Background: Recent neuroimaging studies implicate nigrostriatal degeneration as a critical factor in producing late-onset parkinsonism in patients with L-dopa-responsive dystonia-causing mutations. However, postmortem anatomical studies do not reveal neurodegeneration in L-dopa-responsive dystonia patients. These contrasting findings make it unclear how parkinsonism develops in L-dopa-responsive dystonia mutation carriers. Methods: We prospectively assessed motor dysfunction, responses to dopaminergic challenge, and dopamine neuron degeneration with aging in a validated knockin mouse model bearing a L-dopa-responsive dystonia-causing mutation found in humans. Results: As L-dopa-responsive dystonia mice aged, dystonic movements waned while locomotor activity decreased and initiation of movements slowed. Despite the age-related reduction in movement, there was no evidence for degeneration of midbrain dopamine neurons. Presynaptically mediated dopaminergic responses did not change with age in L-dopa-responsive dystonia mice, but responses to D1 dopamine receptor agonists decreased with age. The bradykinesia and tremor associated with adultonset Parkinson's disease result from a deficit in striatal dopamine (DA) caused by the degeneration of nigrostriatal DA neurons. On the other hand, the deficit in striatal DA caused by mutations in genes critical for catecholamine synthesis, including the GTP cyclohydrolase gene (GCH1) and the tyrosine hydroxylase gene (TH), causes L-dopa-responsive dystonia (DRD), which is characterized by childhood-onset generalized dystonia. Although DRD patients may exhibit parkinsonian features in addition to dystonia, 1,2 autopsy findings suggest that DRD is not associated with nigrostriatal DA neuron degeneration.
evidence for degeneration of midbrain dopamine neurons. Presynaptically mediated dopaminergic responses did not change with age in L-dopa-responsive dystonia mice, but responses to D1 dopamine receptor agonists decreased with age. Conclusions: We have demonstrated for the first time the co-occurrence of dystonia and Parkinson's-like features (mainly consisting of hypokinesia) in a genetic mouse model. In this model we show that these features evolve without dopaminergic neurodegeneration, suggesting that postsynaptic plasticity, rather than presynaptic degeneration, may contribute to the development of parkinsonism in patients with L-dopa-responsive dystonia. The bradykinesia and tremor associated with adultonset Parkinson's disease result from a deficit in striatal dopamine (DA) caused by the degeneration of nigrostriatal DA neurons. On the other hand, the deficit in striatal DA caused by mutations in genes critical for catecholamine synthesis, including the GTP cyclohydrolase gene (GCH1) and the tyrosine hydroxylase gene (TH), causes L-dopa-responsive dystonia (DRD), which is characterized by childhood-onset generalized dystonia. Although DRD patients may exhibit parkinsonian features in addition to dystonia, 1,2 autopsy findings suggest that DRD is not associated with nigrostriatal DA neuron degeneration. 3, 4 However, this assertion has been challenged by recent studies describing a reduction in dopamine transporter (DAT) binding, an indirect indication of nigrostriatal DA neuron degeneration, in patients with DRD-causing mutations but adult-onset parkinsonism. [5] [6] [7] Thus, it was suggested that the presence of DRD-causing mutations predisposes some patients to neurodegenerative Parkinson's disease.
Because it is unclear how the same genetic variant causes DRD in some patients but predisposes others to neurodegeneration and Parkinson's disease, we examined the relationship between these movement disorders and neurodegeneration in a knockin mouse bearing the human DRD-causing p.381Q>K mutation in Th. 8, 9 DRD mice exhibit the core features of DRD in humans including reduced striatal DA concentrations, dystonic movements, and amelioration in response to L-dopa (reference 9, includes video of the dystonia). 9 Here, we demonstrate that dystonia decreases whereas akinesia increases with age in these mice. Furthermore, we demonstrate that the agerelated change in motor dysfunction was associated with functional changes to DA receptor signaling but not nigrostriatal DA neuron degeneration.
Methods Animals
Mice homozygous for the c.1160C>A Th mutation (DRD mice) and normal littermates on a mixed C57BL/ 6J and DBA/2J background were bred and genotyped as previously described. 9 DRD/ 1 mice were crossed, and the pregnant dam's drinking water was supplemented with 100 mg/mL isoproterenol, 20 mg/mL phenylephrine, and 2.5 mg/mL ascorbic acid. From postnatal days 9.5 to 16.5, the dams' drinking water was supplemented with 1.5 mg/mL L-dopa, 0.5 mg/mL benserazide, and 2.5 mg/mL ascorbic acid. Thereafter, all mice received a daily subcutaneous injection of 5 mg/kg L-dopa, 5 mg/ kg benserazide, and 2.5 mg/mL ascorbic acid in saline. All compounds were obtained from Sigma-Aldrich (St. Louis, MO) except isoproterenol (TCI America, Portland, OR). L-Dopa supplementation was terminated more than 24 hours prior to all experiments. Housing conditions were in accordance with Emory University's institutional animal care and use committee. Mice were group-housed with nestlets and "igloos" for environmental enrichment and fed Mouse Diet 5015 (www. labdiet.com). Male and female mice were used because we previously found no differences between the sexes. 9 The light period was 7 AM to 7 PM.
Behavioral Assessments
Assessments were performed prospectively from 1 to 15 months of age. An abnormal movement inventory was used to identify the type of abnormal movement. 10 Abnormal movements included tonic flexion, tonic extension, clonus, twisting, and tremor. Abnormal movements were scored for 30 seconds in 10-minute intervals for 60 minutes in a novel open field at 2 PM, and the scores were summed. Locomotor activity was recorded in automated activity cages (San Diego Instruments) at 2 PM for 60 minutes. To test for the ability to initiate voluntary movement, mice were tested at 8 AM, whereby the forepaws were gently placed on a horizontal bar (0.5-cm diameter), 3 cm above the cage floor. Time to remove both forepaws from the bar was recorded. Cutoff time was 1 minutes, and 3 consecutive trials were averaged.
11
This test is similar to the test that is classically used to assess catalepsy in response to antipsychotic drugs. However, because antipsychotic drugs were not tested here, the results provide an estimate for latency to initiate movements, similar to akinesia observed in parkinsonism. SKF 81297 and amphetamine (Sigma) were administered (10 mL/kg, subcutaneously) in saline in pseudorandom order 10 minutes prior to behavioral tests.
Histochemical Analyses
Brain tissue was prepared by perfusion fixation with paraformaldehyde solution. For stereological counting, every 6th section was immunostained using TH antibody (1:1000; Pel-Freez, Rogers, AR), reacted with biotinylated goat a-rabbit antibody (1:500; Jackson ImmunoResearch, West Grove, PA), and processed with 3,3-diaminobenzadine (Sigma). 12 An Olympus BX51 light microscope equipped with a motorized stage (MACC500; Ludl Electronic Products, Hawthorne, NY) coupled to a computer with StereoInvestigator software (MicroBrightField, Williston, VT) was used for stereological cell counts of TH-positive cells, which were outlined using a mouse brain atlas as reference 13 to define the borders of the substantia nigra (SN) and ventral tegmental area (VTA). TH-positive cells in every 6th section were counted at 40 3 using the optical fractionator probe with a 55,185-mm 2 counting grid and a 10,000-mm 2 frame with 15-mm depth and 1-mm guard zone. 12 For DAT immunostaining, 3 sections per animal at similar rostral-caudal positions were treated with Citra antigen retrieval reagent (BioGenex, Freemont, CA) for 1 hour at 70 8C prior to incubation with rat a-DAT antibody (1:1000; Millipore, Temecula, CA) and then processed with 3,3-diaminobenzadine.
14 DAT immunohistochemistry was quantified using ImageJ software (NIH, Bethesda, MD). For each DAT-staining experiment, DRD and normal mice were processed in parallel; staining was normalized to normal mouse DAT staining within experiments and expressed as a percent of control. For Fluoro-Jade histochemistry, 6-hydroxydopamine (6OHDA)-treated rat tissue was used as a positive control for neurodegenerating terminals and cell bodies. Briefly, 20 lg of 6OHDA (Sigma-Aldrich) was infused into the striatum, and the mice were sacrificed 35 days later, producing 44% dopaminergic nigral degeneration. 15 Sections were incubated in 0.06% potassium permanganate for 13 minutes, developed in 0.0002% Fluoro-Jade B solution (Millipore) for 20 minutes, and imaged with a Nikon 80i fluorescent microscope; results were replicated in a second experiment.
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Experimental Design and Statistical Analysis
Blinding and randomization were performed by second-party concealment with coded syringes. A priori power analyses using means, standard deviations, and effect sizes from Rose et al 9 were used to determine sample sizes that achieved 80% statistical power at a 5 0.05. Statistical analyses were performed using SigmaStat (Systat Software). For 2-group comparisons, Student t tests were performed; 1-tailed t tests were performed based on previously published results. 9 For more than 2 groups, 1-way or 2-way repeated-measures analyses of variance (ANOVAs) were performed. Post hoc effects were tested with the Holm-Sidak test or Tukey's post hoc test if there was no obvious baseline condition. Detailed statistics are presented in the figure legends.
Results
Age-related changes in motor symptoms are sometimes observed in DRD patients. 2, 16, 17 Therefore, we prospectively quantified abnormal movements, including tonic flexion or extension and clonic movements, in DRD mice from 1 month of age, a juvenile developmental stage, through 15 months old, late in the typical life span of a mouse. Abnormal movements increased during adolescence, peaked at 2.5 to 4 months of age, and ebbed in 12-to 15-month-old mice (P < 0.05 for 2.5 or 3 months vs 1, 1.5, 12, and 15 months and P < 0.05 for 4 months vs 12 and 15 months, Tukey's post hoc test; Fig. 1A ). Normal littermates never exhibited dystonic movements (not shown). Some reports suggest that prolonged L-dopa treatment in DRD patients induces dyskinetic side effects, 18 whereas others suggest that the response is stable over time. 19 Like patients, DRD mice received daily L-dopa treatments throughout life. L-Dopa abolished abnormal movements in 15-month-old DRD mice (Fig. 1B) . Abnormal movements in DRD mice were also significantly reduced by both the D1-type dopamine receptor (D1R) agonist SKF 81297 and the D2-type dopamine receptor agonist quinpirole (Fig.  1B) . Thus, dyskinetic movements were not observed in response to either indirect-or direct-acting agonists, despite chronic lifelong L-dopa treatment.
We also prospectively assessed locomotor activity in normal and DRD mice. Overall, locomotor activity decreased with age in both DRD and normal mice. However, based on the significant genotype 3 age interaction effect ( Fig. 2A) , the age-related changes in locomotor activity of normal and DRD mice did not occur in parallel. After an initial early increase in locomotor activity, normal mouse activity gradually declined with age. In contrast, 1-month-old DRD mice were hyperactive, similar to the hyperactivity in rats deprived of DA as neonates. 20 Thereafter, DRD and normal mouse locomotor activity was comparable until 12 months of age, when DRD mice exhibited a reduction in locomotor activity compared with agematched normal littermates. To assess the initiation of voluntary movements, we tested the ability of a mouse to escape an imposed abnormal posture. Normal mice immediately escaped, regardless of age. DRD mice showed a mean latency to move of 12 seconds at 3 months of age, and the mean latency to move increased to 28 seconds at 15 months of age. (Fig.  2B) . L-Dopa treatment abolished the deficit in the ability to initiate voluntary movement in DRD mice.
To determine if the hypokinetic motor dysfunction in aged DRD mice is associated with nigrostriatal degeneration, we assessed midbrain DA neurons in 15-month-old normal and DRD mice using immunostaining for TH. We have previously demonstrated that the number of midbrain DA neurons in 3-monthold DRD mice is comparable to normal mice. 9 Consistent with results in 3-month-old DRD mice. 9 TH staining in 15-month-old DRD mice was weaker than in normal mice (Fig. 3A) , likely because of the instability of the p.381Q>K mutant TH protein. 21 However, there was no difference in the number of midbrain TH-positive neurons between aged normal and DRD mice (Fig. 3D) . DAT immunostaining, a marker of DA terminals, was also similar in 15-month-old DRD and normal mice (Fig. 3B,C) . Finally, a direct assessment of neurodegeneration using Fluoro-Jade staining did not reveal Fluoro-Jadelabeled cells in 15-month-old normal or DRD mice, whereas many Fluoro-Jade-positive cells were observed in the 6OHDA-lesioned positive control tissue (Fig.  3E) . Taken together, these results suggest that overt neurodegeneration does not likely explain the agerelated decline in motor activity in DRD mice.
It is possible that age-related changes in DA release 22 account for the change in motor behaviors. Because the striatal DA concentration in DRD mice is too low to assess extracellular DA using microdialysis or fast scan cyclic voltammetry, we instead exploited the locomotor response to amphetamine, which stimulates presynaptic DA release, as an indirect measure of presynaptic function. Both 3-and 15-month-old normal and DRD mice exhibited a significant increase in locomotor activity in response to 4 mg/kg amphetamine compared with saline ( Fig. 4A, B) . Consistent with studies in aging rats, 23 amphetamine-induced locomotor activity was attenuated in normal 15-month-old mice compared with 3-month-old mice (P < 0.01; Fig. 4B ). In contrast, the locomotor response to amphetamine was comparable in young and aged DRD mice (Fig. 4A) , suggesting that 
a change in presynaptic dopaminergic tone does not likely account for the reduction in locomotor activity and deficit in the ability to initiate movement in aged DRD mice. Because we have previously demonstrated that postsynaptic D1R responses are supersensitive in young DRD mice, 9 we hypothesized that a decrement in the D1R receptor response may be associated with the age-related motor dysfunction. Therefore, we assessed locomotor activity in response to the D1R agonist SKF 81297 in young and aged mice. Although overall locomotor activity was attenuated in 15-monthold normal mice compared with 3-month-old normal mice (Fig. 4D) , the EC 50 for SKF 81297-induced motor activity was 1 mg/kg in both ages. In contrast, the EC 50 for SKF 81297 in 3-month-old DRD mice was 0.08 mg/kg, but increased to 0.2 mg/kg in 15-month-old DRD mice (Fig. 4C ). The highest dose tested in young DRD mice was 0.2 mg/kg SKF 81297 because doses as low as 0.5 mg/kg sometimes caused seizures, a phenomenon normally associated with 10-fold higher doses. 24 In contrast, 1 mg/kg SKF 81297 never induced seizures in aged DRD mice, another indication that D1R sensitivity is reduced with age.
Discussion
Recent genetic and imaging studies implicate nigrostriatal degeneration as a critical factor in producing late-onset parkinsonism in patients with DRD-causing mutations. [5] [6] [7] Although these observations have led to speculation that these mutations cause degenerative Parkinson's disease, postmortem anatomical studies have not found evidence of neurodegeneration in DRD patients. 3, 4 Using a mouse model of DRD, which facilitated prospective behavioral, functional, and anatomical analyses that are not feasible in patients, we have demonstrated that as dystonic movements waned with age, hypokinesia and akinesia, increased in DRD mice. The hypokinesia and akinesia combined with the dopamine deficiency in aged DRD mice resemble some aspects of parkinsonism, although it must be acknowledged that parkinsonism is . A significant age 3 dose interaction effect was observed in DRD mice (F 3,36 5 7.86; P < 0.001, 2-way repeated-measures ANOVA), where a significant difference between saline and 0.08 mg/kg SKF 81297 was observed in 3-monthold DRD mice (P < 0.001, Holm-Sidak post hoc test) but not in 15-month-old DRD mice (P > 0.1, Holm-Sidak post hoc test). In normal mice, there was a significant main effect of dose (F 5,60 5 34.6; P < 0.001, 2-way repeated-measures ANOVA) and age (F 1,12 5 21.8; P < 0.001, 2-way repeatedmeasures ANOVA), but there was not an age 3 dose interaction effect (F 5,60 5 1.91; P > 0.1, 2-way repeated-measures ANOVA). Saline baseline and maximum SKF 81297-stimulated locomotor activity were not significantly different between normal and DRD mice at either 3 or 15 months of age (Student t test). Values represent mean 6 SEM; **P < 0.01, ***P < 0.001. [Color figure can be viewed at wileyonlinelibrary.com] associated with specific signs and symptoms in humans that are difficult to translate precisely in mice. DRD patients also appear to exhibit a similar phenotypic shift with age, 2, 16, 25 although, to our knowledge, no controlled longitudinal cohort study akin to the one performed here with DRD mice has been performed with DRD patients. Despite the age-related increase in hypokinesia, decrements in midbrain DA neuron numbers and presynaptically mediated dopaminergic responses were not observed in aged DRD mice, demonstrating that the hypokinetic features evolved without the neurodegeneration and concomitant reduction in presynaptically mediated DA neurotransmission associated with classic Parkinson's disease. In contrast, we identified an age-related postsynaptic decrement in D1R agonist sensitivity that could account for, at least in part, the behavioral changes. Although a more extensive analysis of postsynaptic changes is needed to reveal detailed mechanisms, our results suggest that neurodegeneration may not be required to produce the age-related parkinsonism that is often observed in DRD and suggest the alternative hypothesis that postsynaptic plasticity contributes to the development of parkinsonism in DRD mutation carriers.
Our results demonstrating that hypokinetic behavior associated with a DA deficit can emerge without nigrostriatal neurodegeneration contrast with recent studies suggesting that neurodegeneration underlies late-onset parkinsonism in DRD mutation carriers. [5] [6] [7] Species differences might account for the discrepant findings. It is also possible that the specific gene defect plays a significant role in determining the fate of dopaminergic neurons; studies in humans all focused on the GCH1 gene for DRD, whereas our studies focused on the TH gene. Approaches used to quantify DA neurons may also account for the different findings. We directly quantified DA neurons in mice. In the human studies, DA neuron integrity was assessed using DAT imaging, which is often used to infer neurodegeneration in Parkinson's disease but does not necessarily correlate with nigral neuron loss. 26 Similarly, loss of DAT occurs in methamphetamine abusers without DA terminal loss. 27 Further, DAT availability is highly regulated 28, 29 and correlated with synaptic DA levels, whereby high DAT expression is associated with high synaptic DA concentrations. 27 Therefore, it is possible that the low DAT availability observed in DRD mutation carriers with adult-onset parkinsonism reflects homeostatic DAT downregulation in response to lifelong low synaptic DA concentrations, considering that these patients have not benefited from chronic dopamine replacement therapy, unlike DRD patients and mice. Postmortem analyses will be useful to discern degeneration, DAT plasticity, or both in these patients.
In both DRD and Parkinson's disease, it is not uncommon for patients to exhibit both dystonia and parkinsonism, but the precise mechanism(s) governing the proclivity toward one motor sign or the other is not fully understood, although both are mediated by low synaptic DA concentrations. Here, we have demonstrated for the first time the co-occurrence of dystonia and some features reminiscent of parkinsonism in a mouse model carrying a human disease-causing mutation, which will greatly facilitate the identification of both shared pathophysiologies and abnormalities unique to each disorder. Understanding both shared and unique pathomechanisms has significance not only for DRD but also for Parkinson's disease, in which dystonia is often a comorbid feature.
